Your browser doesn't support javascript.
loading
Neoadjuvant immunotherapy improves outcomes for resectable gastroesophageal junction cancer: A systematic review and meta-analysis.
Wu, Danzhu; Yang, Liyuan; Yan, Yu; Jiang, Zhengchen; Liu, Yinglong; Dong, Peng; Lv, Yajuan; Zhou, Siqin; Qiu, Yiyang; Yu, Xinshuang.
Affiliation
  • Wu D; Clinical Medical College of Jining Medical University, Jining, Shandong Province, China.
  • Yang L; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Yan Y; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Jiang Z; Department of General Surgery, Shandong Provincial Qianfoshan Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Liu Y; Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Dong P; Department of Oncology, The Second Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Taian, Jinan, Shandong, China.
  • Lv Y; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Relea
  • Zhou S; Medical College, Wuhan University of Science and Technology, Wuhan, China.
  • Qiu Y; School of Nursing, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province, China.
  • Yu X; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, National Key Laboratory of Advanced Drug Delivery and Relea
Cancer Med ; 13(9): e7176, 2024 May.
Article in En | MEDLINE | ID: mdl-38716645
ABSTRACT

BACKGROUND:

In recent years, neoadjuvant immunotherapy (NAIT) has developed rapidly in patients with gastroesophageal junction cancer (GEJC). The suggested neoadjuvant treatment regimens for patients with GEJC may vary in light of the efficacy and safety results.

METHODS:

A search of the Cochrane Library, PubMed, Embase, and Web of Science was completed to locate studies examining the safety and effectiveness of NAIT for resectable GEJC. We analyzed the effect sizes (ES) and 95% confidence intervals (CI) in addition to subgroups and heterogeneity. Meta-analyses were performed using Stata BE17 software.

RESULTS:

For these meta-analyses, 753 patients were chosen from 21 studies. The effectiveness of NAIT was assessed using the pathological complete response (pCR), major pathological response (MPR), and nodal downstage to ypN0 rate. The MPR, pCR, and nodal downstage to ypN0 rate values in NAIT were noticeably higher (MPR ES = 0.45; 95% CI 0.36-0.54; pCR ES = 0.26; 95% CI 0.21-0.32; nodal downstage to ypN0 rate ES = 0.60; 95% CI 0.48-0.72) than those of neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy (nCRT) (MPR < 30%; pCR ES = 3%-17%; nodal downstage to ypN0 rate ES = 21%-29%). Safety was assessed using the treatment-related adverse events (trAEs) incidence rate, surgical delay rate, surgical complications incidence rate, and surgical resection rate. In conclusion, the incidence of trAEs, incidence of surgical complications, and surgical delay rate had ES values of 0.66, 0.48, and 0.09, respectively. These rates were comparable to those from nCT or nCRT (95% CI 0.60-0.70; 0.15-0.51; and 0, respectively). The reported resection rates of 85%-95% with nCT or nCRT were comparable to the mean surgical resection rate of 90%.

CONCLUSION:

NAIT is an effective treatment for resectable GEJC; additionally, the level of NAIT toxicity is acceptable. The long-term effects of NAIT require further study.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Neoadjuvant Therapy / Esophagogastric Junction / Immunotherapy Limits: Humans Language: En Journal: Cancer Med Year: 2024 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Stomach Neoplasms / Esophageal Neoplasms / Neoadjuvant Therapy / Esophagogastric Junction / Immunotherapy Limits: Humans Language: En Journal: Cancer Med Year: 2024 Type: Article Affiliation country: China